ArticleBlood2011
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis.Annals of hematology · 2022Pooled it
- Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in PediatricJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Article
- CD135 (FLT3 receptor) expression as an indicator of prognosis in patients with de novo acute myeloid leukemia.Annals of hematology · 2026Article
- Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.Blood advances · 2024Article
- Fusion and flow: refining risk prediction inTranslational pediatrics · 2023Article
- Comprehensive analysis of clinical prognostic features and tumor microenvironment landscape of CD11bCellular oncology (Dordrecht, Netherlands) · 2023Article
- Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.Cancer medicine · 2023Article
- Straight to the Point-The Novel Strategies to Cure Pediatric AML.International journal of molecular sciences · 2022Review
- Non-GCB Diffuse Large B-Cell Lymphoma With an Atypical Disease Course: A Case Report and Clinical Exome Analysis.World journal of oncology · 2022Article
- Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia.Cancers · 2021Article
- The clinical and biological characteristics of NUP98-KDM5A in pediatric acute myeloid leukemia.Haematologica · 2021Article
- Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.Frontiers in pharmacology · 2021Article
- Acute myeloid leukemia with 11q23 rearrangements: A study of therapy-related disease and therapeutic outcomes.Leukemia research · 2020Article
- Transcriptional addiction in mixed lineage leukemia: new avenues for target therapies.Blood science (Baltimore, Md.) · 2019Review
- The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.Leukemia · 2019Article
- RecurrentBlood advances · 2018Article
- Reemergence of translocation t(11;19)(q23;p13.1) in the absence of clinically overt leukemia.International journal of hematology · 2017Article
- A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome.Leukemia · 2017Article
- The Partial Duplication of the 5' Segment ofCase reports in pediatrics · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
Abstract
We previously demonstrated that outcome of pediatric 11q23/MLL-rearranged AML depends on the translocation partner (TP). In this multicenter international study on 733 children with 11q23/MLL-rearranged AML, we further analyzed which additional cytogenetic aberrations (ACA) had prognostic significance. ACAs occurred in 344 (47%) of 733 and were associated with unfavorable outcome (5-year overall survival [OS] 47% vs 62%, P < .001). Trisomy 8, the most frequent specific ACA (n = 130/344, 38%), independently predicted favorable outcome within the ACAs group (OS 61% vs 39%, P = .003; Cox model for OS hazard ratio (HR) 0.54, P = .03), on the basis of reduced relapse rate (26% vs 49%, P < .001). Trisomy 19 (n = 37/344, 11%) independently predicted poor prognosis in ACAs cases, which was partly caused by refractory disease (remission rate 74% vs 89%, P = .04; OS 24% vs 50%, P < .001; HR 1.77, P = .01). Structural ACAs had independent adverse prognostic value for event-free survival (HR 1.36, P = .01). Complex karyotype, defined as ≥ 3 abnormalities, was present in 26% (n = 192/733) and showed worse outcome than those without complex karyotype (OS 45% vs 59%, P = .003) in univariate analysis only. In conclusion, like TP, specific ACAs have independent prognostic significance in pediatric 11q23/MLL-rearranged AML, and the mechanism underlying these prognostic differences should be studied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.